Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-01
What Is Tesofensine? Benefits, Research & Safety
A triple monoamine reuptake inhibitor originally developed for neurological conditions, now researched for its potent effects on appetite suppression and weight loss.
Also known as:
NS2330
TE
Educational Content Only: This page provides research-based information for educational purposes. Tesofensine is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.
Quick Facts
Category
Fat Loss & Metabolic
Half-Life
Approximately 8-9 days (very long half-life)
UK Status
Not approved. Investigational compound only.
EU Status
Not approved. Remains in clinical development.
Overview
Tesofensine is a novel pharmacological compound originally developed for the treatment of Parkinson's disease and Alzheimer's disease by NeuroSearch A/S in Denmark. While it did not prove effective for these neurological indications, clinical trials unexpectedly revealed significant weight loss effects, redirecting research interest toward obesity treatment.
Tesofensine works by inhibiting the reuptake of three key neurotransmitters: noradrenaline (norepinephrine), dopamine, and serotonin. This triple monoamine reuptake inhibition distinguishes it from most other weight loss medications and produces potent effects on appetite suppression and energy expenditure.
Clinical trials have demonstrated weight loss of up to 10-13% of body weight over six months—results that were exceptional compared to other weight loss medications available at the time. The compound also showed improvements in metabolic parameters including glucose control and lipid profiles.
Despite promising efficacy data, tesofensine's development has been complicated by safety concerns related to cardiovascular effects, particularly increases in heart rate. The compound remains in clinical development, with ongoing research aimed at finding doses that balance efficacy with safety.
Tesofensine is not approved for use in any country and remains an investigational compound.
Discovery & History
Tesofensine was developed by NeuroSearch A/S, a Danish pharmaceutical company specialising in central nervous system drugs. The compound was originally designed as a treatment for Parkinson's disease and Alzheimer's disease based on its ability to enhance monoaminergic neurotransmission.
Phase II trials for Parkinson's disease in the early 2000s did not demonstrate sufficient efficacy for this indication. However, researchers observed that trial participants experienced significant weight loss—an unexpected finding that prompted investigation of tesofensine for obesity treatment.
The TIPO-1 and TIPO-2 Phase II obesity trials, published around 2008-2010, showed remarkable weight loss results. At the 0.5 mg dose, participants lost an average of 12.8 kg (approximately 13% of body weight) over 24 weeks—unprecedented results for a weight loss drug.
However, the trials also revealed dose-dependent increases in heart rate (7-8 beats per minute at the 0.5 mg dose), raising cardiovascular safety concerns that complicated regulatory path forward.
NeuroSearch later licensed tesofensine to Saniona, which continued development at lower doses aimed at achieving a better benefit-risk profile. The compound remains in clinical development but has not achieved regulatory approval.
Mechanism of Action
Tesofensine's mechanism of action involves inhibition of the reuptake of three monoamine neurotransmitters:
**Noradrenaline (Norepinephrine) Reuptake Inhibition**
By blocking noradrenaline reuptake, tesofensine increases sympathetic nervous system activity, potentially enhancing thermogenesis and energy expenditure. This contributes to increased metabolic rate.
**Dopamine Reuptake Inhibition**
Enhanced dopaminergic signalling affects reward pathways and may reduce food cravings and the rewarding aspects of eating. This can help reduce compulsive eating behaviours and make dietary restriction more manageable.
**Serotonin Reuptake Inhibition**
Increased serotonergic activity promotes satiety and reduces appetite. Serotonin plays a key role in signalling fullness to the brain after eating.
**Combined Effects on Appetite and Metabolism**
The triple reuptake inhibition produces additive or synergistic effects on appetite suppression and energy expenditure that exceed what would be achieved by targeting any single neurotransmitter system alone.
**Cardiovascular Considerations**
The sympathomimetic effects of noradrenaline reuptake inhibition lead to increases in heart rate, which has been the main safety concern in clinical development.
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Substantial weight loss of 10-13% in clinical trials
- 2Significant appetite suppression
- 3Potential enhancement of metabolic rate
- 4Improved glycaemic control in obese patients
- 5Reductions in waist circumference
- 6Improved lipid profiles
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | 0.25-0.5 mg daily in clinical trials (investigational) |
| Frequency | Once daily |
| Duration | 24 weeks in Phase II trials |
| Notes | Tesofensine is an investigational compound not approved for use. The information provided reflects clinical trial protocols and is for educational purposes only. The compound should not be used outside of clinical research settings. |
Administration Routes
Routes studied in research settings (educational only):
- Oral administration (capsule form in trials)
| Half-Life | Stability |
|---|---|
| Approximately 8-9 days (very long half-life) | Stable in appropriate pharmaceutical formulations |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Increased heart rate (dose-dependent)
- Dry mouth
- Constipation
- Insomnia
- Headache
- Nausea
Rare Risks & Concerns
- Cardiovascular events (theoretical concern due to heart rate increase)
- Psychiatric effects (related to monoamine modulation)
- Blood pressure changes
- Potential for abuse/dependence (dopaminergic effects)
Contraindications
- Cardiovascular disease
- Uncontrolled hypertension
- History of psychiatric disorders
- Concurrent use of MAO inhibitors
- Pregnancy and breastfeeding
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not approved. Investigational compound only.
🇪🇺 European Union
Not approved. Remains in clinical development.
Tesofensine has not received regulatory approval in any country. It remains an investigational drug with ongoing development efforts focused on optimising the benefit-risk profile.
Clinical Studies Summary
TIPO-1: Tesofensine for Obesity - Phase II Trial
Demonstrated dose-dependent weight loss of up to 12.8 kg (13%) at 0.5 mg dose over 24 weeks, with significant appetite suppression.
Lancet. 2008;372(9653):1906-13View on PubMed
Looking for Tesofensine?
Source research-grade Tesofensine from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Research Guides
Related Peptides
AOD-9604
A modified fragment of human growth hormone specifically researched for its fat-metabolising properties without the growth-promoting effects of full HGH.
Learn moreSemaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreLiraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreSemaglutide
A once-weekly GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, representing a breakthrough in metabolic medicine with average weight loss of 15-17% in clinical trials.
Learn more